GRAIL, Inc. (GRAL)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with GRAL?
Powered by Yahoo ScoutGRAIL's stock surged 15.8%in August, driven by anticipation of an FDA advisory meeting on September 23 regarding its Galleri multi-cancer test. Despite a $110 millionnet loss in Q2, strong test volume growth and a strategic investment from Samsung bolster its future prospects.
- Previous Close
80.62 - Open
79.92 - Bid --
- Ask --
- Day's Range
78.50 - 80.43 - 52 Week Range
35.39 - 118.84 - Volume
-- - Avg. Volume
-- - Market Cap (intraday)
3.588B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Recent News
Statistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (5yr expected)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
--
-
Return on Assets (ttm)
--
-
Return on Equity (ttm)
--
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
--
-
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
-
Total Cash (mrq)
--
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
--
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
